|
Positron Emission Tomography Using Carbon-11 Acetate and Fludeoxyglucose F 18 in Detecting Hepatocellular Carcinoma (Liver Cancer) in Patients With Known or Suspected Liver Cancer Clinical Trials Information presented on Clinical Trials Search isn't intended to be a substitute for proven healthcare advice, trips or treatment using a real physician. We are not docs. Always confer with your mD on Positron Emission Tomography Using Carbon-11 Acetate and Fludeoxyglucose F 18 in Detecting Hepatocellular Carcinoma (Liver Cancer) in Patients With Known or Suspected Liver Cancer conditions. Clinical Trials Search.org is a site dedicated to listing clinical research studies in human subjects. Positron Emission Tomography Using Carbon-11 Acetate and Fludeoxyglucose F 18 in Detecting Hepatocellular Carcinoma (Liver Cancer) in Patients With Known or Suspected Liver Cancer Clinical research trials and Positron Emission Tomography Using Carbon-11 Acetate and Fludeoxyglucose F 18 in Detecting Hepatocellular Carcinoma (Liver Cancer) in Patients With Known or Suspected Liver Cancer medical trials take place in hundreds of localities across the U.S.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials usually measure the effectiveness of new drugs. The intention of the studies / projects is to resolve certain human health questions. Clinical trials are a popular means for physicians, government agencies, and private sector corporations to detect remedies for all forms of circumstances, like Positron Emission Tomography Using Carbon-11 Acetate and Fludeoxyglucose F 18 in Detecting Hepatocellular Carcinoma (Liver Cancer) in Patients With Known or Suspected Liver Cancer. Positron Emission Tomography Using Carbon-11 Acetate and Fludeoxyglucose F 18 in Detecting Hepatocellular Carcinoma (Liver Cancer) in Patients With Known or Suspected Liver Cancer Clinical Trials and other clinical trials allow for volunteers to undergo healthcare treatment options before they are available to the masses. Most times the participants receive treatment for free, and every now and again they are paid for their time. Occasionally there is a cost for a Positron Emission Tomography Using Carbon-11 Acetate and Fludeoxyglucose F 18 in Detecting Hepatocellular Carcinoma (Liver Cancer) in Patients With Known or Suspected Liver Cancer clinical trial. Subjects typically recieve the finest healthcare available for their Positron Emission Tomography Using Carbon-11 Acetate and Fludeoxyglucose F 18 in Detecting Hepatocellular Carcinoma (Liver Cancer) in Patients With Known or Suspected Liver Cancer condition. Hazards are a reality, nonetheless, and might include more or frequent mD trips, health risks (potentially life-endangering), and/or the treatment being ineffective. Trials are federally regulated with stern guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "P" Clinical Trials Conditions > Positron Emission Tomography Using Carbon-11 Acetate and Fludeoxyglucose F 18 in Detecting Hepatocellular Carcinoma (Liver Cancer) in Patients With Known or Suspected Liver Cancer  Positron Emission Tomography Using Carbon-11 Acetate and Fludeoxyglucose F 18 in Detecting Hepatocellular Carcinoma (Liver Cancer) in Patients With Known or Suspected Liver Cancer
Positron Emission Tomography Using Carbon-11 Acetate and Fludeoxyglucose F 18 in Detecting Hepatocellular Carcinoma (Liver Cancer) in Patients With Known or Suspected Liver Cancer
For Condition: adult primary hepatocellular carcinoma,recurrent adult primary liver cancer,localized resectable adult primary liver cancer
Status: Recruiting
Sponsor(s): Washington University Siteman Cancer Center , National Cancer Institute (NCI)
Synopsis: RATIONALE: Imaging procedures, such as carbon-11 acetate positron emission tomography (PET) and fludeoxyglucose F 18 PET, may improve the ability to detect hepatocellular carcinoma (liver cancer) and allow doctors to plan the most effective treatment. PURPOSE: Diagnostic trial to compare the effectiveness of carbon-11 acetate PET with that of fludeoxyglucose F 18 PET in detecting cancer in patients who have liver cancer.
Details: OBJECTIVES: - Determine, preliminarily, the relative sensitivity and specificity of positron emission tomography (PET) scanning with carbon-11 acetate and fludeoxyglucose F 18 for detection of hepatocellular carcinoma (HCC) in patients with known or highly suspected HCC. - Determine whether these PET scans identify additional sites of disease not detected by conventional imaging in these patients. - Determine, preliminarily, the impact of these PET scans on the management of these patients. OUTLINE: This is a nonrandomized, pilot study. Patients undergo carbon-11 acetate-positron emission tomography (PET) over approximately 1 hour followed by fludeoxyglucose F 18-PET over approximately 2 hours. Any positive findings noted by the PET scans are confirmed by repeat CT scan, MRI, and/or bone scintigraphy at approximately 6 months after the PET scans are performed. Biopsy confirmation is performed where indicated. Patients with discrepency between the PET scans and conventional imaging OR with unclarified PET scan results are followed at 6 months. PROJECTED ACCRUAL: A total of 30 patients will be accrued for this study within 18 months.
Eligibility:
Study Type: Interventional, Diagnostic
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: DISEASE CHARACTERISTICS: - Diagonosis of one of the following: - Histologically confirmed hepatocellular carcinoma (HCC) - Stage I or stage II disease by conventional staging - Prior HCC with a new primary tumor OR recurrent HCC allowed - Clinically documented cirrhosis meeting at least one of the following criteria: - Alpha-fetoprotein > 200 mg/dL - Contrast-enhancing tumor mass 1 cm by CT scan or MRI - Tumor mass confirmed by arteriography - Scheduled for routine clinical fludeoxyglucose F 18-positron emission tomography PATIENT CHARACTERISTICS: Age - 18 and over Performance status - Not specified Life expectancy - Not specified Hematopoietic - Not specified Hepatic - See Disease Characteristics Renal - Not specified Other - No poorly controlled diabetes mellitus (fasting blood glucose > 200 mg/dL) - No other malignancy within the past 5 years except basal cell skin cancer or carcinoma in situ of the cervix - Not pregnant or nursing - Negative pregnancy test - Fertile patients must use effective contraception PRIOR CONCURRENT THERAPY: Biologic therapy - Not specified Chemotherapy - Not specified Endocrine therapy - Not specified Radiotherapy - Not specified Surgery - Not specified
Total Enrollment:
Location and Contact Information:
Overall Study Official:
WilliamChapman, Study Chair, Washington University Siteman Cancer Center
Siteman Cancer Center *Recruiting*
St. Louis, Missouri, 63110
United States
Recruiting William Chapman 314-361-7792
Additional Information:
Study ID Numbers: CDR0000358907; WU-03-0771
Study Start Date:
Record last reviewed: March 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00081094
Other Localized Resectable Adult Primary Liver Cancer Studies:
1. T900607 in Treating Patients With Unresectable Liver Cancer
2. Sho-Saiko-To Following Removal of Liver Cancer By Embolization in Treating Patients With Liver Cancer That Cannot Be Surgically Removed
3. Thalidomide and Chemoembolization With Doxorubicin in Treating Patients With Liver Cancer That Cannot be Removed by Surgery
4. TAC-101 in Treating Patients With Advanced Hepatocellular Carcinoma (Liver Cancer)
5. DX-8951f in Treating Patients With Liver Cancer
Related Studies:
Other localized resectable adult primary liver cancer Clinical Trials
Other Missouri Clinical Trials
Other St. Louis Clinical Trials
Positron Emission Tomography Using Carbon-11 Acetate and Fludeoxyglucose F 18 in Detecting Hepatocellular Carcinoma (Liver Cancer) in Patients With Known or Suspected Liver Cancer
|
|
|
|
|
|
|
|
